AbbVie (ABBV) said to win its case against Coherus (CHRS)

November 7, 2016 12:13 PM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

AbbVie (NYSE: ABBV) said to win its case against Coherus BioSciences (NASDAQ: CHRS), according to market chatter. The litigation involved AbbVie's U.S. patent 9,114,166, which relates to its arthritis drug Humira.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Litigation, Trader Talk

Add Your Comment